37 active not recruiting. 37 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Active not recruiting 37 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Daratumumab SC, Clarithromycin, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 11 | 2021-10-28 | 2026-05-20 |
| Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Carfilzomib, Dexamethasone, Isatuximab - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | University of Washington | 30 | 2021-07-29 | 2026-09-16 |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Carfilzomib, Dexamethasone, Pomalidomide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 39 | 2021-05-06 | 2026-02-25 |
| Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib ixazomib-pomalidomide-dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Tel-Aviv Sourasky Medical Center | 61 | 2021-03-25 | 2026-08-11 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Daratumumab, Carfilzomib, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Andrew Yee, MD | 44 | 2020-05-18 | 2026-10-15 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-08-08 | 2026-06-01 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-07-24 | 2026-10-15 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-10-15 | 2026-11-05 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-08-20 | 2026-09-15 |
| SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma Selinexor, Daratumumab, Bortezomib - Refractory Multiple Myeloma | Phase 2 | Active not recruiting | PETHEMA Foundation | 62 | 2018-07-15 | 2026-02-27 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-06-20 | 2026-11-05 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) Afatinib, Biopsy Procedure, Biospecimen Collection - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2018-02-28 | 2026-07-17 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 16 | 2017-08-21 | 2026-11-05 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) Adavosertib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2017-03-24 | 2026-11-03 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-12 | 2026-11-03 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2017-03-12 | 2026-11-05 |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2016-11-01 | 2026-07-17 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) Biopsy Procedure, Biospecimen Collection, Crizotinib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2016-07-29 | 2026-03-19 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) Biopsy Procedure, Biospecimen Collection, Crizotinib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2016-07-20 | 2026-10-19 |
Showing 20 of 37. Sign in to see all of them.
Multiple Myeloma (37) · Lymphoma (30) · Hematologic Neoplasms (17) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Lung Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Blood Protein Disorders (37) · Cardiovascular Diseases (37) · Hematologic Diseases (37) · Hemic and Lymphatic Diseases (37) · Hemorrhagic Disorders (37) · Hemostatic Disorders (37) · Immune System Diseases (37) · Immunoproliferative Disorders (37) · Lymphoproliferative Disorders (37) · Neoplasms (37) · Neoplasms by Histologic Type (37) · Neoplasms, Plasma Cell (37) · Paraproteinemias (37) · Vascular Diseases (37) · Lymphatic Diseases (30)
Biopsy (16) · Specimen Handling (15) · Magnetic Resonance Spectroscopy (13) · Crizotinib (5) · Dexamethasone (5) · Nuclear Medicine Department, Hospital (5) · X-Rays (5) · trametinib (5) · pomalidomide (4) · Afatinib (3) · GSK2636771 (3) · carfilzomib (3) · copanlisib (3) · sapanisertib (3) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (2)
National Cancer Institute (NCI) (30) · Andrew Yee, MD (1) · Mayo Clinic (1) · Multiple Myeloma Research Consortium (1) · PETHEMA Foundation (1) · Tel-Aviv Sourasky Medical Center (1) · University of Washington (1) · Weill Medical College of Cornell University (1)
United States (35) · Guam (1) · Israel (1) · Puerto Rico (1) · Spain (1)
David S Hong (3) · Filip Janku (3) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Aaron S Mansfield (1) · Alain C Mita (1) · Alice T Shaw (1) · Andrew J Yee, MD (1) · Anne S Tsao (1) · Chezi Ganzel, MD (1) · David M Jackman (1) · Douglas B Johnson (1) · Erin R Macrae (1) · Evgeni Chubar, MD (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40153687, PMID 40865033, PMID 41066729, PMID 41533998, PMID 41556942, PMID 42719971
U10CA180820 (30), U24CA196172 (17)